The Rb/E2F pathway and cancer
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Over the past decade, studies focusing on the mechanisms controlling cellular proliferation have converged with equally intensive efforts directed at the analysis of oncogenic pathways associated with human cancer. These convergent studies have revealed the central role played by the pathway that controls the activity of the retinoblastoma tumor suppressor protein (Rb), which in turn regulates the E2F transcription factor. In particular, it is now clear that the Rb/E2F pathway is critical in regulating the initiation of DNA replication. It is also clear that the control of the pathway is disrupted in virtually all human cancers. Questions remain, however, as to the specific role played by individual activities within the pathway in the control of cell growth and their participation in the development of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379 · cited 1×
“Both amplification as well as translocation of the D1 cyclin gene has been observed in a variety of human cancers and amplification of the cdk4 gene has been seen in sarcomas and gliomas ( 35 ).”
BackgroundThe retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601 · cited 1×
“One such case of relevance to colon cancer is the recent demonstration of ar ole forβ-catenin/Tcf4 in the activation of cyclin D1 expression ( 46 ).”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Mdm2 had previously been shown to function as a p53 ubiquitin ligase, targeting p53 for destruction (28, 29 ).”
BackgroundA human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
Friend, S. H., Bernards, R., Rogelj, S., Weinberg, R. A., Rapaport, J. M., Albert, D. M., & Dryja, T. P. (1986) · Nature · doi:10.1038/323643a0 · Cited by 2,948 · cited 2×
“The retinoblastoma gene was initially identified as a genetic locus associated with the development of an inherited eye tumor (1, 2 ).”
BackgroundA cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Cited by
Yue, Z., Jin, S., Yang, C., Levine, A. J., & Heintz, N. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2436255100 · Cited by 2,116
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
“RB, p130, and p107 physically interact with many proteins, but their binding to members of the E2F family of transcription factors appears to be central to their role in governing DNA replication (Dyson, 1998; Nevins, 2001; Trimarchi and Lees, 2002).”
BackgroundInfluentialFry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Role of interleukin-6 in cancer progression and therapeutic resistance
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5098-7 · Cited by 1,092
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,034
Emerging roles of E2Fs in cancer: an exit from cell cycle control
Chen, H.-Z., Tsai, S.-Y., & Leone, G. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2696 · Cited by 1,021
Biomarkers, oxidative stress and autophagy in skin aging
Gu, Y., Han, J., Jiang, C., & Zhang, Y. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101036 · Cited by 762
Bretones, G., Delgado, M. D., & León, J. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.03.013 · Cited by 747
The E2F transcriptional network: old acquaintances with new faces
Dimova, D. K., & Dyson, N. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208612 · Cited by 715
Lassen, P., Eriksen, J. G., Hamilton-Dutoit, S., Tramm, T., Alsner, J., & Overgaard, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.2853 · Cited by 612
HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells
Satou, Y., Yasunaga, J.-I., Yoshida, M., & Matsuoka, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507631103 · Cited by 593
E2F target genes: unraveling the biology
Bracken, A. P., Ciro, M., Cocito, A., & Helin, K. (2004) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.06.006 · Cited by 576
Histological classification and molecular genetics of meningiomas
Riemenschneider, M. J., Perry, A., & Reifenberger, G. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70625-1 · Cited by 573
Coordination of ER and oxidative stress signaling: The PERK/Nrf2 signaling pathway
Cullinan, S. B., & Diehl, J. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.09.018 · Cited by 554
Mitsiades, C. S., Mitsiades, N. S., McMullan, C. J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536759100 · Cited by 531
G‐Quadruplexes: Targets in Anticancer Drug Design
Ou, T., Lu, Y., Tan, J., Huang, Z., Wong, K., & Gu, L. (2008) · ChemMedChem · doi:10.1002/cmdc.200700300 · Cited by 482
Cyclins and cdks in development and cancer: a perspective
Deshpande, A., Sicinski, P., & Hinds, P. W. (2005) · Oncogene · doi:10.1038/sj.onc.1208618 · Cited by 464
RB1: a prototype tumor suppressor and an enigma
Dyson, N. J. (2016) · Genes & Development · doi:10.1101/gad.282145.116 · Cited by 435
Review of Osteosarcoma and Current Management
Durfee, R. A., Mohammed, M., & Luu, H. H. (2016) · Rheumatology and Therapy · doi:10.1007/s40744-016-0046-y · Cited by 395
Cln3 Activates G1-Specific Transcription via Phosphorylation of the SBF Bound Repressor Whi5
de Bruin, R. A. M., McDonald, W. H., Kalashnikova, T. I., Yates, J., & Wittenberg, C. (2004) · Cell · doi:10.1016/j.cell.2004.05.025 · Cited by 385
i-Motif DNA: Structure, stability and targeting with ligands
Day, H. A., Pavlou, P., & Waller, Z. A. E. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.047 · Cited by 383
Extra-embryonic function of Rb is essential for embryonic development and viability
Wu, L., de Bruin, A., Saavedra, H. I., Starovic, M., Trimboli, A., Yang, Y., Opavska, J., Wilson, P., Thompson, J. C., Ostrowski, M. C., et al. (2003) · Nature · doi:10.1038/nature01417 · Cited by 383
Prevalent Overexpression of Prolyl Isomerase Pin1 in Human Cancers
Bao, L., Kimzey, A., Sauter, G., Sowadski, J. M., Lu, K. P., & Wang, D.-G. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63731-5 · Cited by 378
Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus
Berk, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1209040 · Cited by 377
PP2A as a master regulator of the cell cycle
Wlodarchak, N., & Xing, Y. (2016) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2016.1143913 · Cited by 371
Fusaro, G., Dasgupta, P., Rastogi, S., Joshi, B., & Chellappan, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305171200 · Cited by 348
Tailoring to RB: tumour suppressor status and therapeutic response
Knudsen, E. S., & Knudsen, K. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2401 · Cited by 344
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 344
Lee, J.-S., Leem, S.-H., Lee, S.-Y., Kim, S.-C., Park, E.-S., Kim, S.-B., Kim, S.-K., Kim, Y.-J., Kim, W.-J., & Chu, I.-S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0977 · Cited by 342
Signaling Networks That Link Cell Proliferation and Cell Fate
Sears, R. C., & Nevins, J. R. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.r100063200 · Cited by 336
Self-citationvon Knebel Doeberitz, M. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00462-8 · Cited by 330
Nicotine induces cell proliferation by -arrestin-mediated activation of Src and Rb-Raf-1 pathways
Dasgupta, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28164 · Cited by 311
Elkon, R., Linhart, C., Sharan, R., Shamir, R., & Shiloh, Y. (2003) · Genome Research · doi:10.1101/gr.947203 · Cited by 297
The genetics of the E2F family of transcription factors: shared functions and unique roles
DeGregori, J. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00051-3 · Cited by 295
Coordinated regulation of life and death by RB
Chau, B. N., & Wang, J. Y. J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc993 · Cited by 292
“10, 3051–3064 (1996). 24. Wang, J., Guo, K., Wills, K. N. & Walsh, K. Rb functions to inhibit apoptosis during myocyte differentiation. Cancer Res. 57, 351–354 (1997). 25. Ferguson, K. L. et al. Telencephalon-specific Rb knockouts reveal enhanced neurogenesis, survival and abnormal cortical development. EMBO J. 21, 33…”
BackgroundInfluentialThe p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting
Fingerle-Rowson, G., Petrenko, O., Metz, C. N., Forsthuber, T. G., Mitchell, R., Huss, R., Moll, U., Müller, W., & Bucala, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533295100 · Cited by 284
Myc Requires Distinct E2F Activities to Induce S Phase and Apoptosis
Leone, G., Sears, R., Huang, E., Rempel, R., Nuckolls, F., Park, C.-H., Giangrande, P., Wu, L., Saavedra, H. I., Field, S. J., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00275-1 · Cited by 268
Self-citationGatza, M. L., Silva, G. O., Parker, J. S., Fan, C., & Perou, C. M. (2014) · Nature Genetics · doi:10.1038/ng.3073 · Cited by 258
Schulte-Sasse, R., Budach, S., Hnisz, D., & Marsico, A. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00325-y · Cited by 256
MYC Oncogene Contributions to Release of Cell Cycle Brakes
García-Gutiérrez, L., Delgado, M. D., & León, J. (2019) · Genes · doi:10.3390/genes10030244 · Cited by 255
PIN1 Is an E2F Target Gene Essential for Neu/Ras-Induced Transformation of Mammary Epithelial Cells
Ryo, A., Liou, Y.-C., Wulf, G., Nakamura, M., Lee, S. W., & Lu, K. P. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5281-5295.2002 · Cited by 253
Reactivation of mutant p53: molecular mechanisms and therapeutic potential
Selivanova, G., & Wiman, K. G. (2007) · Oncogene · doi:10.1038/sj.onc.1210295 · Cited by 186
“Nevins JR. (2001). The Rb/E2F pathway and cancer.”
BackgroundKümper, S., Mardakheh, F. K., McCarthy, A., Yeo, M., Stamp, G. W., Paul, A., Worboys, J., Sadok, A., Jørgensen, C., Guichard, S., et al. (2016) · eLife · doi:10.7554/elife.12203 · Cited by 186
“blocking E2F-dependent transcription (Brenner et al., 1998; Nevins, 2001).”
InfluentialA Cell Proliferation and Chromosomal Instability Signature in Anaplastic Thyroid Carcinoma
Salvatore, G., Nappi, T. C., Salerno, P., Jiang, Y., Garbi, C., Ugolini, C., Miccoli, P., Basolo, F., Castellone, M. D., Cirafici, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1887 · Cited by 182
“The E2F family of transcription factors includes positive (E2F1-3) and negative (E2F4-6) regulators of cell cycle progression (28, 29).”
BackgroundInvolvement of E2F transcription factor family in cancer
Tsantoulis, P. K., & Gorgoulis, V. G. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.005 · Cited by 163
“It is noteworthy that, with the exception of the trinucleotide repeat region in E2F4, the E2F family is generally not a common target for mutations in cancer as we [131] and others [165] have noticed (also reviewed in [166]).”
BackgroundA comprehensive modular map of molecular interactions in RB/E2F pathway
Calzone, L., Gelay, A., Zinovyev, A., Radvanyi, F., & Barillot, E. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.7 · Cited by 132
Tate, S. C., Cai, S., Ajamie, R. T., Burke, T., Beckmann, R. P., Chan, E. M., De Dios, A., Wishart, G. N., Gelbert, L. M., & Cronier, D. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2846 · Cited by 130
Frank, C. L., & Tsai, L.-H. (2009) · Neuron · doi:10.1016/j.neuron.2009.03.029 · Cited by 118
“Kept inactive by the Retinoblastoma (Rb) tumor suppressor protein, E2F proteins are activated as Rb becomes hyper-phosphorylated by CDK4, CDK6, and CDK2/ cyclin E over the course of G1 progression (Nevins, 2001).”
Gao, Q., Chen, K., Gao, L., Zheng, Y., & Yang, Y.-G. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.155 · Cited by 110
“Cyclin D1 and CDK4/6 coregulate cell cycle progression by phosphorylating and thereby inhibiting retinoblastoma (RB),(22,23) which allows E2F-mediated S-phase gene transcription, such as CDK1, CDK2, Cyclin A, Cyclin E1 and Ki67.(24,25) Taken together, these results demonstrated a critical role for CD47 in the regulati…”
BackgroundRb inactivation leads to E2F1-mediated DNA double-strand break accumulation
Pickering, M. T., & Kowalik, T. F. (2006) · Oncogene · doi:10.1038/sj.onc.1209103 · Cited by 108
Disruption of the Rb-Raf-1 Interaction Inhibits Tumor Growth and Angiogenesis
Dasgupta, P., Sun, J., Wang, S., Fusaro, G., Betts, V., Padmanabhan, J., Sebti, S. M., & Chellappan, S. P. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.21.9527-9541.2004 · Cited by 98
“Inactivation of Rb by phosphorylation leads to the dissociation and activation of E2F, allowing the expression of many genes required for cell cycle progression and S-phase entry (5, 7, 48).”
BackgroundPechnick, R. N., Zonis, S., Wawrowsky, K., Cosgayon, R., Farrokhi, C., Lacayo, L., & Chesnokova, V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027290 · Cited by 78
“In mammalian cells, the control of proliferation primarily occurs in the G1 phase of the cell cycle [12].”
BackgroundTabach, Y., Milyavsky, M., Shats, I., Brosh, R., Zuk, O., Yitzhaky, A., Mantovani, R., Domany, E., Rotter, V., & Pilpel, Y. (2005) · Molecular Systems Biology · doi:10.1038/msb4100030 · Cited by 72
Selective CDK6 degradation mediated by cereblon, VHL, and novel IAP-recruiting PROTACs
Anderson, N. A., Cryan, J., Ahmed, A., Dai, H., McGonagle, G. A., Rozier, C., & Benowitz, A. B. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127106 · Cited by 69
Cdc2: A monopotent or pluripotent CDK?
Hu, X., & Moscinski, L. C. (2011) · Cell Proliferation · doi:10.1111/j.1365-2184.2011.00753.x · Cited by 69
E2F-1 Is Essential for Normal Epidermal Wound Repair
D'Souza, S. J. A., Vespa, A., Murkherjee, S., Maher, A., Pajak, A., & Dagnino, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111956200 · Cited by 59
Kong, L.-J., Meloni, A. R., & Nevins, J. R. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.02.016 · Cited by 48
Self-citationCell Permeable Iron Chelators as Potential Cancer Chemotherapeutic Agents
Pahl, P. M. B., & Horwitz, L. D. (2005) · Cancer Investigation · doi:10.1080/07357900500359976 · Cited by 40
E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice
Moreno, E., Toussaint, M. J. M., van Essen, S. C., Bongiovanni, L., van Liere, E. A., Koster, M. H., Yuan, R., van Deursen, J. M., Westendorp, B., & de Bruin, A. (2021) · Hepatology · doi:10.1002/hep.31259 · Cited by 37
“This is important, because RB is inactivated, mutated, or lost in a wide array of human cancers.(9,10) Manipulation of E2F7/8 can uncouple E2F target gene transcription from pRb activity.”
BackgroundThe effects of bufadienolides on HER2 overexpressing breast cancer cells
Wang, T., Mu, L., Jin, H., Zhang, P., Wang, Y., Ma, X., Pan, J., Miao, J., & Yuan, Y. (2016) · Tumor Biology · doi:10.1007/s13277-015-4381-3 · Cited by 15
Metadata
- Authors
- Nevins, J. R.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-04-01
- Volume
- 10
- Issue
- 7
- Pages
- 699-703
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2149139293
- Cited by
- 922
- References
- 54
- FWCI
- 19.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.